Stockreport

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates [Yahoo! Finance]

SAB Biotherapeutics, Inc.  (SABS) 
PDF company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), [Read more]